Plain-English translation of NCT07013149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is watching what happens to people with pulmonary arterial hypertension (a serious condition affecting blood vessels in the lungs) when they switch from one blood pressure medication called ambrisentan to another called bosentan. Researchers want to understand whether this switch affects how well the treatment works and whether people experience different side effects.
Many patients had to switch medications because of a shortage of ambrisentan, but doctors don't have good information about whether this medication change helps or harms people in the long run. This study will help answer that real-world question.
You likely qualify if…
You likely don't qualify if…
If you join, you'll continue your regular doctor visits — this is not an experimental treatment study. Doctors will review your medical records and measure how you're doing using standard health assessments, blood tests, and functional ability checks. They'll compare your health between 3 and 6 months after a medication switch (or during the same timeframe if you stayed on the same medication) to see how the changes affected you.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
Brazil
Enrollment target
~183 participants
Started
August 2025
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Caio Fernandes, Principal Investigator
University of Sao Paulo General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.